Supplement IDS submitted herewith. U.S. Patent No. 5,688,651 was cited in the Supplemental IDS submitted August 25, 2000. At the request of the Examiner, U.S. Patent No. 5,688,651 was cited a second time in the Supplemental IDS filed on August 20, 2001.

Support for the amendment to claim 1 is found throughout the specification as filed. No new matter has been added with this amendment. Claim 1 has been amended to recite a disease characterized by amyloid deposit "comprising Aβ peptide." Support for the amendment may be found, *e.g.*, in the specification on page 1, lines 26-27 and page 41, line 31 to page 42, line 5. Claim 1 has been amended to recite an antibody that specifically binds to the "Aβ peptide." Support for the amendment may be found, *e.g.*, in the specification on page 2, lines 25-28; page 3, lines 1-4; page 14, line 14 to page 15, line 2; page 57, lines 25-31; page 58, Table 6; and, in claims 1, 9, 25-28, and 57-58 as originally filed. Claim 1 has been amended to recite in a regime effective to prevent or treat the disease "wherein the administering of the antibody reduces levels of Aβ in the brain of the patient." Support for the amendment may be found, *e.g.*, at page 72, line 17 to page 78, line 10 of Example XI.

Claims depending from canceled claim 9, namely, claims 10-15, 20-24, 29, and 31, have been amended to depend from claim 2.

Support for new claims 68-81 is found throughout the specification. Support for new claims 68 and 75 is found, *e.g.*, at page 78, lines 12-26. Support for new claims 69 and 74 is found, *e.g.*, at page 3, lines 5-6; page 28, lines 11-13; and, in claim 22 as originally filed. Support for new claims 70, 71, 76, and 77 is found, *e.g.*, at page 28, lines 17-21. Support for new claims 72 and 78 is found, *e.g.*, at page 28, lines 19-20. Support for new claims 73 and 79 is found, *e.g.*, at page 35, lines 31-33. Support for new claims 80 and 81 is found, *e.g.*, at page 2, lines 30-33; page 3, lines 2-3; page 14, lines 29-30; page 28, lines 22-24; and in claims 10 and 11 as originally filed. In view of the foregoing support, Applicant believes no new matter has been introduced and respectfully request the new claims 68-81 be entered.

Applicant believes that no fee is required for submission of this second Amendment. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400
Fax: (650) 326-2422
RLC:lah
PA 3236775 v1

VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. (Twice amended) A method of preventing or treating a disease characterized by amyloid deposit comprising Aβ peptide in a patient, comprising administering to the patient an antibody that specifically binds to Aβ peptide[the amyloid deposit or a component thereof], in a regime effective to prevent or treat the disease, wherein the administering of the antibody reduces levels of Aβ in the brain of the patient.

10. The method of claim 2[9], wherein the antibody is a human antibody.

11. The method of claim 2[9], wherein the antibody is a humanized antibody.

12. The method of claim 2[9], wherein the antibody is a chimeric antibody.

13. The method of claim 2[9], wherein the antibody is a mouse antibody.

14. The method of claim 2[9], wherein the antibody is a polyclonal antibody.

15. The method of claim 2[9], wherein the antibody is a monoclonal antibody.

20. The method of claim 2[9], wherein the antibody is a Fab fragment.

21. The method of claim 2[9], wherein a chain of the antibody is fused to a heterologous polypeptide.

22. The method of claim 2[9], wherein the dosage of antibody is at least 1 mg/kg body weight of the patient.

23. The method of claim 2[9], wherein the dosage of antibody is at least 10 mg/kg body weight of the patient.

24. The method of claim 2[9], wherein the antibody is administered with a carrier as a pharmaceutical composition.

29. The method of claim 2[9], wherein the antibody is a human antibody to Aβ prepared from B cells from a human immunized with an Aβ peptide.

31. The method of claim 2[9], wherein the antibody specifically binds to Aβ peptide without binding to full-length amyloid precursor protein (APP).